7-Year-Old Gets Dream Wheelchair-Accessible Tree House
Hayden’s Journey: 2 months after his NCIM stem cell treatment (Patient blogsite)
Email Updates from Dani Smith’s Mum (Spina Bifida)
What follows below are 2 emails* sent to Nova Cell Institute by the mother of Danielle “Dani” Smith, a little girl with spina bifida who has been the subject of 2 prior blog entries on this website:
“Dani Smith Walks” – You Tube Video update
Continue reading Email Updates from Dani Smith’s Mum (Spina Bifida)
Wharton’s Jelly Stem Cells: safety & more
ADVANTAGES OF WHARTON’S JELLY STEM CELLS ESPECIALLY MESENCYMALS (Designated as WJ-MSC for convenience below) ESPECIALLY WITH RESPECT TO SAFETY
WJ HAS MORE STEM CELLS THAN EITHER BONE MARROW OR ADIPOSE TISSUE
The quantity of mesenchymal stem cells which can typically be obtained from bone marrow is far less than that Wharton’s Jelly: 0.001 to 0.01% mononuclear cells from BM, with 1 g of adipose tissue yielding ~ 5 × 103 stem cells, and Wharton’s jelly 1 to 5 × 104 cells/cm of umbilical cord. In side-by-side comparison studies of MSC from bone marrow adipose tissue and Wharton’s jelly, WJ-MSCs had the highest proliferative capacity.
WJ STEM CELLS ARE MORE PRIMITIVE THAN OTHER ADULT STEM CELL TYPES YET DO NOT PRODUCE TUMORS AND ACTUALLY HAVE ANTI-TUMOR EFFECTS IN VITRO (Lab dish) AND IN VIVO (In living animals & humans)
WJ-MSC differ from other adult MSCs with respect to the fact they demonstrate far more primitive characteristics e.g., they express embryonic-like stem cell markers including pluripotency genes, Oct-4, Nanog, and SOX-2 but at levels well below that of embryonic stem (ESC) cells. Despite this, WJ-MSCs do not form tumors (teratomas). This is attributed to the fact that WJ-MS’s have a lower expression of pluripotency genes than embryonic stem cells (ESCs being very pluripotent and by virtue of this are prone to develop teratomas when injected into animals or humans). When WJ-MSCs were injected in immunocompromised and immunodeficient animals they still failed to form tumors.
Also: WJ-MSCs express low levels of the embryonic stem cell pluripotency markers POUF1, NANOG, SOX2 and LIN28, which also plays a role in the fact they do not produce teratomas. WJ-MSCs also synthesize and express several cytokines including IL12A which is associated with the induction of apoptosis (programmed cell death) which is believed to underlie their ability to lyse (eradicate) tumor cells.
Furthermore, the transcriptome of WJ-MSC and ESC differs substantially in that WJ-MSCs demonstrate high expression levels of several tumor suppressor genes and suppresses tumors both in vitro and in vivo. Moreover, large quantities of tumor growth inhibiting cytokines and growth factors are secreted by WJ-MSCs. Also, WJ-MSC cell lysates as well as the conditioned medium they are cultured in strongly inhibited the growth of breast adenocarcinoma, ovarian carcinoma, osteosarcoma, benign neoplastic keloid cells, bladder tumor, and lymphoma cells in vitro. When WJ-MSC cell lysates and conditioned medium were injected into mammary carcinoma, osteosarcoma, and pancreatic and lung tumors it inhibited their growth and shrank the tumors in vivo .
WJ-MSCs DO NOT CAUSE IMMUNE REJECTION OR ADVERSE REACTIONS
WJ-MSCs have also been found to be immunoprivileged which is to say they escape rejection or adverse immune reactions. Part of the reason for this lies in the fact WJ-MSCs have low MHC-I levels and an absence of MHC-II expression. And, though they synthesize low amounts of MHC class I, WJ-MSCs have no immunogenicity. Research indicates that this is due to the fact they do not express costimulatory molecules such as CD 40, CD80, CD86, and also produce high levels of immune response inhibitors such as indoleamine-2,3-dioxygenase (IDO), prostaglandin E2 (PGE2) and leukocyte antigen G6 (HLA-G6).
NOVA CELLS INSTITUTE HARVESTS & MAKES CLINICAL USE OF STEM CELLS ISOLATED FROM (UMBILICAL CORD) WHARTON’S JELLY CELLS: https://ncimx.wordpress.com/2015/03/15/whartons-jelly-stem-cells/
ADDITIONAL REFERENCES – NIH PubMed results (5-1-2016)
| Wharton’s Jelly-derived mesenchymal stem cells alleviate memory deficits and reduce amyloid-β deposition in an APP/PS1 transgenic mouse model. | |
| Xie ZH, Liu Z, Zhang XR, Yang H, Wei LF, Wang Y, Xu SL, Sun L, Lai C, Bi JZ, Wang XY. | |
| Clin Exp Med. 2016 Feb;16(1):89-98. doi: 10.1007/s10238-015-0375-0. Epub 2015 Jul 19. | |
| PMID: 26188488 [PubMed – in process] | |
| Similar articles |
| Therapeutic influence of intraperitoneal injection of Wharton’s jelly-derived mesenchymal stem cells on oviduct function and fertility in rats with acute and chronic salpingitis. | |
| Luo HJ, Xiao XM, Zhou J, Wei W. | |
| Genet Mol Res. 2015 Apr 17;14(2):3606-17. doi: 10.4238/2015.April.17.10. | |
| PMID: 25966129 [PubMed – indexed for MEDLINE] Free Article | |
| Similar articles |
| Effect of human Wharton’s jelly mesenchymal stem cell secretome on proliferation, apoptosis and drug resistance of lung cancer cells. | |
| Hendijani F, Javanmard ShH, Rafiee L, Sadeghi-Aliabadi H. | |
| Res Pharm Sci. 2015 Mar-Apr;10(2):134-42. | |
| PMID: 26487890 [PubMed] Free PMC Article | |
| Similar articles |
| Preserved β-cell function in type 1 diabetes by mesenchymal stromal cells. | |
| Carlsson PO, Schwarcz E, Korsgren O, Le Blanc K. | |
| Diabetes. 2015 Feb;64(2):587-92. doi: 10.2337/db14-0656. Epub 2014 Sep 9. | |
| PMID: 25204974 [PubMed – indexed for MEDLINE] Free Article | |
| Similar articles |
| . | The Potential of Wharton’s Jelly Derived Mesenchymal Stem Cells in Treating Patients with Cystic Fibrosis. |
| Boruczkowski D, Gładysz D, Demkow U, Pawelec K. | |
| Adv Exp Med Biol. 2015;833:23-9. doi: 10.1007/5584_2014_17. Review. | |
| PMID: 25248343 [PubMed – indexed for MEDLINE] | |
| Similar articles |
| Wharton’s jelly derived mesenchymal stem cells: future of regenerative medicine? Recent findings and clinical significance. | |
| Kalaszczynska I, Ferdyn K. | |
| Biomed Res Int. 2015;2015:430847. doi: 10.1155/2015/430847. Epub 2015 Mar 15. Review. | |
| PMID: 25861624 [PubMed – indexed for MEDLINE] Free PMC Article | |
| Similar articles |
| Undifferentiated Wharton’s Jelly Mesenchymal Stem Cell Transplantation Induces Insulin-Producing Cell Differentiation and Suppression of T-Cell-Mediated Autoimmunity in Nonobese Diabetic Mice. | |
| Tsai PJ, Wang HS, Lin GJ, Chou SC, Chu TH, Chuan WT, Lu YJ, Weng ZC, Su CH, Hsieh PS, Sytwu HK, Lin CH, Chen TH, Shyu JF. | |
| Cell Transplant. 2015;24(8):1555-70. doi: 10.3727/096368914X683016. Epub 2014 Jul 15. | |
| PMID: 25198179 [PubMed – in process] | |
| Similar articles |
| Effects of Wharton’s jelly-derived mesenchymal stem cells on neonatal neutrophils. | |
| Khan I, Zhang L, Mohammed M, Archer FE, Abukharmah J, Yuan Z, Rizvi SS, Melek MG, Rabson AB, Shi Y, Weinberger B, Vetrano AM. | |
| J Inflamm Res. 2014 Dec 31;8:1-8. doi: 10.2147/JIR.S71987. eCollection 2015. | |
| PMID: 25678809 [PubMed] Free PMC Article | |
| Similar articles |
| A comparison of Wharton’s jelly and cord blood as a source of mesenchymal stem cells for diabetes cell therapy. | |
| El-Demerdash RF, Hammad LN, Kamal MM, El Mesallamy HO. | |
| Regen Med. 2015;10(7):841-55. doi: 10.2217/rme.15.49. Epub 2015 Nov 6. | |
| PMID: 26541176 [PubMed – in process] | |
| Similar articles |
| . | Comparisons of Differentiation Potential in Human Mesenchymal Stem Cells from Wharton’s Jelly, Bone Marrow, and Pancreatic Tissues. |
| Kao SY, Shyu JF, Wang HS, Lin CH, Su CH, Chen TH, Weng ZC, Tsai PJ. | |
| Stem Cells Int. 2015;2015:306158. doi: 10.1155/2015/306158. Epub 2015 Jul 29. | |
| PMID: 26294917 [PubMed] Free PMC Article | |
| Similar articles |
| . | Roles of the co-culture of human umbilical cord Wharton’s jelly-derived mesenchymal stem cells with rat pancreatic cells in the treatment of rats with diabetes mellitus. |
| Wang G, Li Y, Wang Y, Dong Y, Wang FS, Ding Y, Kang Y, Xu X. | |
| Exp Ther Med. 2014 Nov;8(5):1389-1396. Epub 2014 Sep 22. | |
| PMID: 25289028 [PubMed] Free PMC Article | |
| Similar articles |
| Comprehensive characterization of four different populations of human mesenchymal stem cells as regards their immune properties, proliferation and differentiation. | |
| Li X, Bai J, Ji X, Li R, Xuan Y, Wang Y. | |
| Int J Mol Med. 2014 Sep;34(3):695-704. doi: 10.3892/ijmm.2014.1821. Epub 2014 Jun 25. | |
| PMID: 24970492 [PubMed – indexed for MEDLINE] Free PMC Article | |
| Similar articles |
| Safety and feasibility of umbilical cord mesenchymal stem cells in treatment-refractory systemic lupus erythematosus nephritis: time for a double-blind placebo-controlled trial to determine efficacy. | |
| Woodworth TG, Furst DE. | |
| Arthritis Res Ther. 2014 Jul 30;16(4):113. doi: 10.1186/ar4677. | |
| PMID: 25166210 [PubMed – indexed for MEDLINE] Free PMC Article | |
| Similar articles |
| A preliminary evaluation of efficacy and safety of Wharton’s jelly mesenchymal stem cell transplantation in patients with type 2 diabetes mellitus. | |
| Liu X, Zheng P, Wang X, Dai G, Cheng H, Zhang Z, Hua R, Niu X, Shi J, An Y. | |
| Stem Cell Res Ther. 2014 Apr 23;5(2):57. doi: 10.1186/scrt446. | |
| PMID: 24759263 [PubMed – indexed for MEDLINE] Free PMC Article | |
| Similar articles |
| Protein synthesis and secretion in human mesenchymal cells derived from bone marrow, adipose tissue and Wharton’s jelly. | |
| Amable PR, Teixeira MV, Carias RB, Granjeiro JM, Borojevic R. | |
| Stem Cell Res Ther. 2014 Apr 16;5(2):53. doi: 10.1186/scrt442. | |
| PMID: 24739658 [PubMed – indexed for MEDLINE] Free PMC Article | |
| Similar articles |
| Therapeutic effect of transplanted human Wharton’s jelly stem cell-derived oligodendrocyte progenitor cells (hWJ-MSC-derived OPCs) in an animal model of multiple sclerosis. | |
| Mikaeili Agah E, Parivar K, Joghataei MT. | |
| Mol Neurobiol. 2014 Apr;49(2):625-32. doi: 10.1007/s12035-013-8543-2. Epub 2013 Aug 28. | |
| PMID: 23982748 [PubMed – indexed for MEDLINE] | |
| Similar articles |
| Microvesicles derived from human Wharton’s Jelly mesenchymal stromal cells ameliorate renal ischemia-reperfusion injury in rats by suppressing CX3CL1. | |
| Zou X, Zhang G, Cheng Z, Yin D, Du T, Ju G, Miao S, Liu G, Lu M, Zhu Y. | |
| Stem Cell Res Ther. 2014 Mar 19;5(2):40. doi: 10.1186/scrt428. | |
| PMID: 24646750 [PubMed – indexed for MEDLINE] Free PMC Article | |
| Similar articles |
| . | Effect of combined therapy of human Wharton’s jelly-derived mesenchymal stem cells from umbilical cord with sitagliptin in type 2 diabetic rats. |
| Hu J, Wang F, Sun R, Wang Z, Yu X, Wang L, Gao H, Zhao W, Yan S, Wang Y. | |
| Endocrine. 2014 Mar;45(2):279-87. doi: 10.1007/s12020-013-9984-0. Epub 2013 May 18. | |
| PMID: 23686639 [PubMed – indexed for MEDLINE] | |
| Similar articles |
| Effect of human Wharton’s jelly mesenchymal stem cell paracrine signaling on keloid fibroblasts. | |
| Arno AI, Amini-Nik S, Blit PH, Al-Shehab M, Belo C, Herer E, Jeschke MG. | |
| Stem Cells Transl Med. 2014 Mar;3(3):299-307. doi: 10.5966/sctm.2013-0120. Epub 2014 Jan 16. | |
| PMID: 24436441 [PubMed – indexed for MEDLINE] Free PMC Article | |
| Similar articles |
| Human Wharton’s jelly mesenchymal stem cells promote skin wound healing through paracrine signaling. | |
| Arno AI, Amini-Nik S, Blit PH, Al-Shehab M, Belo C, Herer E, Tien CH, Jeschke MG. | |
| Stem Cell Res Ther. 2014 Feb 24;5(1):28. doi: 10.1186/scrt417. | |
| PMID: 24564987 [PubMed – indexed for MEDLINE] Free PMC Article | |
| Similar articles |
| . | Characterization of hepatic markers in human Wharton’s Jelly-derived mesenchymal stem cells. |
| Buyl K, De Kock J, Najar M, Lagneaux L, Branson S, Rogiers V, Vanhaecke T. | |
| Toxicol In Vitro. 2014 Feb;28(1):113-9. doi: 10.1016/j.tiv.2013.06.014. Epub 2013 Jun 29. | |
| PMID: 23820183 [PubMed – indexed for MEDLINE] | |
| Similar articles |
| Human Wharton’s Jelly Mesenchymal Stem Cells plasticity augments scar-free skin wound healing with hair growth. | |
| Sabapathy V, Sundaram B, V M S, Mankuzhy P, Kumar S. | |
| PLoS One. 2014 Apr 15;9(4):e93726. doi: 10.1371/journal.pone.0093726. eCollection 2014. | |
| PMID: 24736473 [PubMed – indexed for MEDLINE] Free PMC Article | |
| Similar articles |
| Stem cells from umbilical cord Wharton’s jelly from preterm birth have neuroglial differentiation potential. | |
| Messerli M, Wagner A, Sager R, Mueller M, Baumann M, Surbek DV, Schoeberlein A. | |
| Reprod Sci. 2013 Dec;20(12):1455-64. doi: 10.1177/1933719113488443. Epub 2013 May 13. | |
| PMID: 23670950 [PubMed – indexed for MEDLINE] Free PMC Article | |
| Similar articles |
| Wharton’s jelly-derived mesenchymal stem cells promote myocardial regeneration and cardiac repair after miniswine acute myocardial infarction. | |
| Zhang W, Liu XC, Yang L, Zhu DL, Zhang YD, Chen Y, Zhang HY. | |
| Coron Artery Dis. 2013 Nov;24(7):549-58. doi: 10.1097/MCA.0b013e3283640f00. | |
| PMID: 23892469 [PubMed – indexed for MEDLINE] | |
| Similar articles |
| Reduction of fibrosis in dibutyltin dichloride-induced chronic pancreatitis using rat umbilical mesenchymal stem cells from Wharton’s jelly. | |
| Zhou CH, Li ML, Qin AL, Lv SX, Wen-Tang, Zhu XY, Li LY, Dong Y, Hu CY, Hu DM, Wang SF. | |
| Pancreas. 2013 Nov;42(8):1291-302. doi: 10.1097/MPA.0b013e318296924e. | |
| PMID: 24152954 [PubMed – indexed for MEDLINE] | |
| Similar articles |
| Human Wharton’s jelly-derived mesenchymal stromal cells reduce renal fibrosis through induction of native and foreign hepatocyte growth factor synthesis in injured tubular epithelial cells. | |
| Du T, Zou X, Cheng J, Wu S, Zhong L, Ju G, Zhu J, Liu G, Zhu Y, Xia S. | |
| Stem Cell Res Ther. 2013 Jun 4;4(3):59. doi: 10.1186/scrt215. | |
| PMID: 23734757 [PubMed – indexed for MEDLINE] Free PMC Article | |
| Similar articles |
| Higher propensity of Wharton’s jelly derived mesenchymal stromal cells towards neuronal lineage in comparison to those derived from adipose and bone marrow. | |
| Balasubramanian S, Thej C, Venugopal P, Priya N, Zakaria Z, Sundarraj S, Majumdar AS. | |
| Cell Biol Int. 2013 May;37(5):507-15. doi: 10.1002/cbin.10056. Epub 2013 Feb 18. | |
| PMID: 23418097 [PubMed – indexed for MEDLINE] | |
| Similar articles |
| Immunosuppressive properties of mesenchymal stromal cells derived from amnion, placenta, Wharton’s jelly and umbilical cord. | |
| Manochantr S, U-pratya Y, Kheolamai P, Rojphisan S, Chayosumrit M, Tantrawatpan C, Supokawej A, Issaragrisil S. | |
| Intern Med J. 2013 Apr;43(4):430-9. doi: 10.1111/imj.12044. | |
| PMID: 23176558 [PubMed – indexed for MEDLINE] | |
| Similar articles |
| . | Mesenchymal stem cells derived from Wharton’s Jelly of the umbilical cord: biological properties and emerging clinical applications. |
| Batsali AK, Kastrinaki MC, Papadaki HA, Pontikoglou C. | |
| Curr Stem Cell Res Ther. 2013 Mar;8(2):144-55. Review. | |
| PMID: 23279098 [PubMed – indexed for MEDLINE] | |
| Similar articles |
| Proangiogenic features of Wharton’s jelly-derived mesenchymal stromal/stem cells and their ability to form functional vessels. | |
| Choi M, Lee HS, Naidansaren P, Kim HK, O E, Cha JH, Ahn HY, Yang PI, Shin JC, Joe YA. | |
| Int J Biochem Cell Biol. 2013 Mar;45(3):560-70. doi: 10.1016/j.biocel.2012.12.001. Epub 2012 Dec 12. | |
| PMID: 23246593 [PubMed – indexed for MEDLINE] | |
| Similar articles |
| Mesenchymal stem cells isolated from peripheral blood and umbilical cord Wharton’s jelly. | |
| Trivanović D, Kocić J, Mojsilović S, Krstić A, Ilić V, Djordjević IO, Santibanez JF, Jovcić G, Terzić M, Bugarski D. | |
| Srp Arh Celok Lek. 2013 Mar-Apr;141(3-4):178-86. | |
| PMID: 23745340 [PubMed – indexed for MEDLINE] Free Article | |
| Similar articles |
| Wharton’s jelly or bone marrow mesenchymal stromal cells improve cardiac function following myocardial infarction for more than 32 weeks in a rat model: a preliminary report. | |
| López Y, Lutjemeier B, Seshareddy K, Trevino EM, Hageman KS, Musch TI, Borgarelli M, Weiss ML. | |
| Curr Stem Cell Res Ther. 2013 Jan;8(1):46-59. | |
| PMID: 23270633 [PubMed – indexed for MEDLINE] | |
| Similar articles |
| Perspectives of employing mesenchymal stem cells from the Wharton’s jelly of the umbilical cord for peripheral nerve repair. | |
| Ribeiro J, Gartner A, Pereira T, Gomes R, Lopes MA, Gonçalves C, Varejão A, Luís AL, Maurício AC. | |
| Int Rev Neurobiol. 2013;108:79-120. doi: 10.1016/B978-0-12-410499-0.00004-6. Review. | |
| PMID: 24083432 [PubMed – indexed for MEDLINE] | |
| Similar articles |
| Mesenchymal stem cells from human umbilical cord express preferentially secreted factors related to neuroprotection, neurogenesis, and angiogenesis. | |
| Hsieh JY, Wang HW, Chang SJ, Liao KH, Lee IH, Lin WS, Wu CH, Lin WY, Cheng SM. | |
| PLoS One. 2013 Aug 22;8(8):e72604. doi: 10.1371/journal.pone.0072604. eCollection 2013. | |
| PMID: 23991127 [PubMed – indexed for MEDLINE] Free PMC Article | |
| Similar articles |
| Comparison of mesenchymal stem cells derived from fat, bone marrow, Wharton’s jelly, and umbilical cord blood for treating spinal cord injuries in dogs. | |
| Ryu HH, Kang BJ, Park SS, Kim Y, Sung GJ, Woo HM, Kim WH, Kweon OK. | |
| J Vet Med Sci. 2012 Dec;74(12):1617-30. Epub 2012 Aug 9. | |
| PMID: 22878503 [PubMed – indexed for MEDLINE] Free Article | |
| Similar articles |
| Hydrogen peroxide preconditioning enhances the therapeutic efficacy of Wharton’s Jelly mesenchymal stem cells after myocardial infarction. | |
| Zhang J, Chen GH, Wang YW, Zhao J, Duan HF, Liao LM, Zhang XZ, Chen YD, Chen H. | |
| Chin Med J (Engl). 2012 Oct;125(19):3472-8. | |
| PMID: 23044308 [PubMed – indexed for MEDLINE] Free Article | |
| Similar articles |
| Immune characterization of mesenchymal stem cells in human umbilical cord Wharton’s jelly and derived cartilage cells. | |
| Liu S, Yuan M, Hou K, Zhang L, Zheng X, Zhao B, Sui X, Xu W, Lu S, Guo Q. | |
| Cell Immunol. 2012 Jul-Aug;278(1-2):35-44. doi: 10.1016/j.cellimm.2012.06.010. Epub 2012 Jul 16. | |
| PMID: 23121974 [PubMed – indexed for MEDLINE] | |
| Similar articles |
| Human umbilical cord Wharton’s jelly mesenchymal stem cells do not transform to tumor-associated fibroblasts in the presence of breast and ovarian cancer cells unlike bone marrow mesenchymal stem cells. | |
| Subramanian A, Shu-Uin G, Kae-Siang N, Gauthaman K, Biswas A, Choolani M, Bongso A, Chui-Yee F. | |
| J Cell Biochem. 2012 Jun;113(6):1886-95. doi: 10.1002/jcb.24057. | |
| PMID: 22234854 [PubMed – indexed for MEDLINE] | |
| Similar articles |
| Comparison of human amniotic fluid-derived and umbilical cord Wharton’s Jelly-derived mesenchymal stromal cells: Characterization and myocardial differentiation capacity. | |
| Bai J, Hu Y, Wang YR, Liu LF, Chen J, Su SP, Wang Y. | |
| J Geriatr Cardiol. 2012 Jun;9(2):166-71. doi: 10.3724/SP.J.1263.2011.12091. | |
| PMID: 22916064 [PubMed] Free PMC Article | |
| Similar articles |
| Immunosuppressive function of mesenchymal stem cells from human umbilical cord matrix in immune thrombocytopenia patients. | |
| Ma L, Zhou Z, Zhang D, Yang S, Wang J, Xue F, Yang Y, Yang R. | |
| Thromb Haemost. 2012 May;107(5):937-50. doi: 10.1160/TH11-08-0596. Epub 2012 Mar 8. | |
| PMID: 22398715 [PubMed – indexed for MEDLINE] | |
| Similar articles |
| Comparison of chemokine and receptor gene expression between Wharton’s jelly and bone marrow-derived mesenchymal stromal cells. | |
| Balasubramanian S, Venugopal P, Sundarraj S, Zakaria Z, Majumdar AS, Ta M. | |
| Cytotherapy. 2012 Jan;14(1):26-33. doi: 10.3109/14653249.2011.605119. Epub 2011 Nov 18. | |
| PMID: 22091833 [PubMed – indexed for MEDLINE] | |
| Similar articles |
| Wharton’s Jelly stem cells: future clinical applications. | |
| Taghizadeh RR, Cetrulo KJ, Cetrulo CL. | |
| Placenta. 2011 Oct;32 Suppl 4:S311-5. doi: 10.1016/j.placenta.2011.06.010. Epub 2011 Jul 6. Review. | |
| PMID: 21733573 [PubMed – indexed for MEDLINE] | |
| Similar articles |
| Neuronal plasticity of human Wharton’s jelly mesenchymal stromal cells to the dopaminergic cell type compared with human bone marrow mesenchymal stromal cells. | |
| Datta I, Mishra S, Mohanty L, Pulikkot S, Joshi PG. | |
| Cytotherapy. 2011 Sep;13(8):918-32. doi: 10.3109/14653249.2011.579957. Epub 2011 Jun 22. | |
| PMID: 21696238 [PubMed – indexed for MEDLINE] | |
| Similar articles |
| Wharton’s jelly mesenchymal stem cells as candidates for beta cells regeneration: extending the differentiative and immunomodulatory benefits of adult mesenchymal stem cells for the treatment of type 1 diabetes. | |
| Anzalone R, Lo Iacono M, Loria T, Di Stefano A, Giannuzzi P, Farina F, La Rocca G. | |
| Stem Cell Rev. 2011 Jun;7(2):342-63. doi: 10.1007/s12015-010-9196-4. Review. | |
| PMID: 20972649 [PubMed – indexed for MEDLINE] | |
| Similar articles |
| Immunomodulatory effect of human umbilical cord Wharton’s jelly-derived mesenchymal stem cells on lymphocytes. | |
| Zhou C, Yang B, Tian Y, Jiao H, Zheng W, Wang J, Guan F. | |
| Cell Immunol. 2011;272(1):33-8. doi: 10.1016/j.cellimm.2011.09.010. Epub 2011 Sep 29. | |
| PMID: 22004796 [PubMed – indexed for MEDLINE] Free PMC Article | |
| Similar articles |
Improvements coming out of the gate for Evie Morgan (3 year old little girl with Spina bifida)
Three year old Evie Morgan has spina bifida and a Facebook page devoted to her journey to betterment at https://www.facebook.com/evieswarriors/. She was treated in Mexico by Nova Cells Institute doctors during April (2016) and soon her Mum, Heather, was emailing NCIM a series of positive reports and video clips. Heather also made posts to the aforementioned Facebook page — three of which follow further down below.
On 4-27-16 Heather Morgan sent this email message to NCIM:
We felt very comfortable in the hospital. The room was very clean and had a private bathroom and sink. The pediatrician, Dr. Sanchez, was amazing and Evie loved her so much. Dr. Sanchez spoke great English and we had no trouble understanding her at all. The nurses were very attentive to whatever it was that Evie needed and Grace was always right there to translate for us if they had questions or we wanted to say something. The procedure was quick and painless. Within 5 minutes of receiving the treatment Evie began moving her toes. In the week and a half since treatment Evie is still able to move her toes on command (prior to treatment Evie only had very little involuntary movement of her toes), she is urinating more on her own and has very increased balance. She is now beginning to walk much longer distances with her canes (before she had a walker). At her next urology appointment we are going to be able to start discussing next steps in seeing how her bladder can fully function without medication. We are very pleased with the results we have seen thus far and can’t wait to see what else Evie is going to do!
Evie’s Warriors – Posted on April 22, 2016 (Friday)
This video was taken 2 days after stem cells. Evie is now able to move her toes on command! Before it was completely involuntary movement. Pardon her sassiness at the beginning 😂 Evie also has incredibly improved balance and is able to walk much longer distances with her canes! #evieswarriors
Evie is showing improvements in her bladder function and abilities since yesterday. We aren’t sure if this is going to be a consistent thing but we are definitely watching now. This is nuts.
Sorry for lack of updates. Everything went perfectly and the treatment is now complete. Within minutes Evie was flexing her right ankle when asked and wiggling all 5 toes. Some of the movement is involuntary right now as the cells are being repaired. We will continue to see results for a few months. Thank you all for supporting our girl! #evieswarriors
Video: Little boy with spina bifida is now moving the toes on both his feet
Rikky Foresman is a little boy with spina bifida who had his first stem cell treatment with Nova Cells Institute during early 2014. Last month (March 2016) he underwent another treatment with laboratory primed umbilical cord stem cells and NCIM’s unique & proprietary “Beacon Factor”. It has now been less than 3 weeks since Rikky’s treatment, and on March 29 (2016) his father posted a video of the boy moving the toes on both his feet on the family’s “Blazin’ for Rikky” Facebook page at https://www.facebook.com/BlazinforRikky/?fref=nf
It should also be noted that Rikky began feeling temperature changes in his legs and feet the very next day following his treatment (while at the beach).
HD
This link is to past stories on Rikky that have been posted on this website:
New study underscores how messed up “garbage processing” in neurons causes major problems
NEW STUDY UNDERSCORES HOW MESSED UP “GARBAGE DISPOSAL” PROCESSING IN NEURONS CREATES BIG PROBLEMS: Breaking the brain’s garbage disposal (AUTOPHAGY): Study shows even a small problem causes big effects: http://medicalxpress.com/news/2016-01-brain-garbage-disposal-small-problem.html (1-26-2016)
Many neurodegenerative diseases involve a failure of lysosomes (the “garbage disposal” system within cells including neurons) to do their job properly. Now comes evidence that defective or compromised lysosomes may contribute to Alzheimer’s disease, something ably laid out in a 6-30-15 article on the Medical Express website at http://medicalxpress.com/news/2015-06-failure-cells-garbage-disposal-contribute.html. Here is a salient quote from this article:
Lysosomes, the “garbage disposal” systems of cells, are found in great abundance near the amyloid plaques in the brain that are a hallmark of Alzheimer’s disease. Scientists have long assumed that their presence was helpful—that they were degrading the toxic proteins that trigger amyloid plaque formation.
However, in Alzheimer’s patients, these lysosomes lack the ability to do their jobs properly, and instead of helping, the accumulation of lysosomes may even contribute to the disease, Yale University researchers report the week of June 29 in the Proceedings of the National Academy of Sciences.
The new findings raise the possibility that coaxing lysosomes to do their jobs could help to prevent the toxic processes that eventually destroy the minds of Alzheimer’s patients.
The big question is how to get lysosomes to do their job as they should. While medicine has little that can pull this off, Nova Cells possesses an effective, nontoxic way to do so: Namely its proprietary Beacon Factor. Not surprisingly, many patients with neurologic diseases and conditions that involve fouled up lysosomes have responded quickly and beautifully to intravenous infusions of the Beacon Factor. Click to read some of the case histories.
Jane from the “Show Me” State of Missouri – Older lady with Parkinson’s disease & Lewy Body Dementia
Note by Nova Cell’s patient educator & care facilitator concerning Jane at the time she was picked up for transport to Mexico plus a brief summary of what took place after her Beacon Factor & stem cell treatments:
Jane arrived seated in a wheelchair with both hands and arms shaking, the left more so than the right. I knew from her history that she was no longer able to walk without assistance. Her son and her partner kind of lift and drag her from her wheelchair to other seating. She is incontinent and thus uses adult Pampers. Very thin ones. She came to treatment accompanied by her live-in partner and her son, both of whom are named Paul. She is given to having occasional hallucinations and is not aware of what is going on around her.
Jane was given large doses of the Beacon Factor by IV drip the first day in hospital. At night she asked to be helped to the restroom. Her partner and son helped her though she walked to the bathroom, and was not dragged.
The day after her stem cell infusion by both spinal tap and IV, Jane became more alert and began looking at her partner and son directly and was conversing with them. She didn’t say a whole lot but she was definitely more aware of everything and everyone around her. She even said “What is going on?”
Notes made by Jane’s son Paul and sent to NCIM:
Jan 20, 2016
1 pm PST, drove down from San Diego to TJ .
Checked into the hospital
3 pm PST: She ate some soup with lime Jell-O.
4 pm PST: The doctors put in an IV and began a saline drip. Mom took her usual medication.
5 pm PST: The doctor added the first dose of “The Beacon Factor”. We ordered dinner, tuna fish sandwiches, mixed fruit with bananas, mango and apples, some apple juice and water.
Mom seem to perk up while eating a lot, offering food to her partner and I while discussing how good she felt.
Tested her memory several times, which was still spotty, but she seemed concerned that she was “failing”. Noticed that she had her eyes wide open and answered questions quickly, even though sometimes she didn’t make a lot of sense. We both noticed she had more coherent thought processes and conversation.
7 pm PST: Mom took her final medication of the day.
Jan 21, 2016
6:30 am PST: Arrived back at the hospital. Mom was a bit frantic.
Really need an interpreter the whole time.
Changed bedding and dressings.
7:00 am PST: Mom was given her morning meds.
Took Mom to the restroom.
9:00 am PST: Mom seemed much more lucid, looking around. Finally started to fall back to sleep after eating.
Changed bedding again and her dressings.
She slept until 11:30 am
1 pm PST: Anesthesiologist arrived and introduced himself and the fact he would be giving her a local in her back for the spinal puncture stem cell injection procedure.
2pm – 3pm PST: Talked with Mom who sat up on her own a lot, looked around a great deal, though she was still hallucinating and engaged in some nonsensical talk. Observed what was going on, and looked forward to going home. During conversations she started in with “Come here doggie” and “There’s an old woman, really old, scary, staring at me”
Mom’s facial expressions became much more expressive. She was picking her lips and began folding her blankets and fidgeting a lot.
3 pm PST: The MD arrived to check her blood pressure, heart and blood oxygen level.
3:30 pm PST: Still waiting for them to take her in for her infusion.
She’s asking lots of questions and thinking very clearly after all the “Beacon Factor”.
4:00 pm PST: Mom left to go get stem cells.
5:20 pm PST: Mom was returned to the room, still very groggy from the anesthesia but doing well.
6:00 pm PST: Mom exhibited nearly normal behaviors (for her) of obsessing, and mumbling, but without leaning over as she usually did. More eye movement and she was more concerned over recent events.
8:00 pm PST: Final dose of regular medicines for the day, after which she quickly became very groggy and tired.
9:00 pm PST: Returned to hotel room
Friday Jan 22, 2016
Returned home to Missouri after a day of travel.
Noticed several things, including obsessive behavior though not as extreme. Mom could be easily instructed to lean back, and she looked through the pages of magazines without tearing up the pages as she’d done in the past. During changing, she lifted herself up as instructed. Much more focus than before and she kept up conversations on current topics longer than had been true previously.
Read this before you settle on a stem cell or other treatment or therapy in Mexico or elsewhere
Nova Cells Institute (NCIM) often gets emails from people who ask about stem cell and other therapies done elsewhere but which have little chance of turning things around for them. Here are some of these treatments along with comments by NCIM experts:
(1) Subcutaneous injections of stem cells to treat serious neurologic and other health challenges, including cancer. COMMENT: Subcutaneously injected stem cells may stimulate production of nerve growth factor or other compounds, but is an iffy way to stimulate healing or regeneration unless one is treating a problem very close to the injection site. Depending on the target tissue or organ, stem cells given by intravenous, intrathecal or other routes is more likely to have the desired therapeutic effect.
(2) Nova Cells hears from people who have been told that biochemical signals from injured or diseased tissues will attract infused stem cells. This is true but what they aren’t being told is that these signals fade over time or the injected or infuse stem cells typically do not respond fully to them. COMMENT: Nova Cells director of laboratory services, Dr. Abel Pena, created a nontoxic homing/signal amplification (or “beacon”) compound that stimulates damaged or diseased tissues to send out stronger stem cell attractive signals while simultaneously sensitizing stem cells to recognize and respond to these signals. This compound was dubbed, appropriately enough, the “Beacon Factor” and positively no one has it or anything like it but Nova Cells. You can read more about it by clicking this link.
3) Emails occasionally come in from people saying they have been offered some kind of stem cell or other therapy (for a serious or intractable condition) in Mexico or elsewhere for between $1,000-4,000 USD. COMMENT: The old sayings “If it sounds too good to be true, it is” and “caveat emptor” (Buyer beware) certainly applies here. What NCIM has turned up down through the years (with respect to these “medical blue plate specials”) are instances in which: (a) MDs and others gave patients far fewer cells than claimed. In one particular instance, an office worker in a so-called stem cell clinic reported actually seeing a doctor take a vial labelled as containing 5 million umbilical cord stem cells and placing a small quantity from this into each of ten other vials, then administering these to patients who had paid to get 5 million stem cells each; (b) Patients were given “live cell therapy” (embryonic cells from animals typically lambs) but were told they were getting human umbilical or other adult stem cells: (c) People with advanced, terminal cancer were given low cost treatments that had worked in lab dish or animal studies but bombed out in well designed & executed studies done in humans.
Doing medicine in Mexico is not cheap contrary to what some people think. Unfortunately, there are unscrupulous doctors and clinics that have come up with “cost cutting measures” (like those above) who do a grave disservice to the patients they purport to help.
Nova Cells is able to offer economically priced care, i.e., typically 30% less than other stem cell medicine operations, because it cut out the “middle men”, e.g., professional marketers and public relations people, and was able to get top flight MDs including surgeons on board who believe profits must take a backseat to getting people well. And, its head of laboratory services, Dr. Abel Pena (photo on right), who was trained (in part) by a leading US stem cell biologist, insists on processing & counting all stem cells himself and then priming or programming them (to become cell types that are more likely to effect healing or restoration in a given patient than unprimed stem cells). Dr. Pena personally handles all aspects of stem cell and Beacon Factor processing so as to insure that everything is done to the highest cGMP (manufacturing) standards and the patient is getting exactly what he or she paid for.
Stem cell homing = Better clinical outcomes
Stem cell homing makes a big difference in clinical outcomes. Watch this short video to learn more about how Nova Cells pulls this off.
Nova Cells Institute gets stem cells to target tissues using its Beacon Factor. Learn more by getting our FREE e-book “Heroic Medicine” (Click to download). Read about our successful stem cell treatments for spina bifida, cancer, stroke, dementia, autoimmune diseases, and more. Get your FREE e-book “Heroic Medicine” now!
You’ve got to get stem cells to their target tissue or organ. No one but Nova Cells has a way to reliably pull this off.
If you ever played the game of darts or used a crossbow you know the goal is to hit your target. In the world of stem cell medicine the same holds true. Virtually all stem cell therapy clinics and hospitals infuse or inject stem cells and count on biochemical signals produced by damaged or diseased tissues to “get the darts” (stem cells) to target. This works in principle, yes, but likely winds up with more stem cells lodged in non-target tissues than in the tissues or organ needing healing or restoration. This diminishes responses and outcomes as you would expect.
But what if you switch on a homing system in the stem cells and amplify the signals in diseased or damaged tissues or organs? More “darts” or “biologic missiles” (stem cells) will hit their mark!
No stem cell clinic or such anywhere has a biologic “guidance & homing signal amplification system” that helps get stem cells to target. None, that is, but Nova Cells Institute which pulls this off thanks to its proprietary Beacon Factor. You can read more about the Beacon Factor by clicking this link.
You will also find information on the Beacon Factor in Nova Cells Institute’s just published e-book titled “Heroic Medicine”, which is free for downloading at http://www.novacellsinstitute.com/pdf/Heroic%20Medicine.pdf
LAB PRIMED STEM CELLS. DONOR IMMUNE CELLS FOR CANCER. STEM CELL HOMING BEACON FACTOR. +1-562-916-3410. 